Next onboarding starts March/April 2025 - Reserve your spot now
LIMITEDActive Outreach That Accelerates Recruitment
We proactively engage physicians worldwide in their native languages, based on precise protocol matching, cutting recruitment timelines by up to half.
Protocol-Based Outreach
We actively identify and contact physicians with relevant patient populations based on precise protocol matching, not just passively waiting for inquiries.
Clinical Expertise
Our communications demonstrate deep understanding of medical conditions, treatment options, and protocol nuances while maintaining an empathetic, patient-focused approach.
NCT04866563 Trial - Potential Match
Hi Sara,
I recently read your paper on "Cognitive Fluctuations as Early Predictors of Amyloid Accumulation in Pre-symptomatic Alzheimer's" and was particularly interested in your findings about the correlation between episodic memory fluctuations and subsequent amyloid positivity.
This connects directly with the NCT04866563 trial we're recruiting for. Their mechanism targets the specific tau-amyloid interaction pathways you highlighted in your discussion section, and they're seeing promising early results in modulating those precise cognitive fluctuation patterns you identified as predictive biomarkers.
For reference, they're looking for patients with:
- Early-stage Alzheimer's (MMSE 20-26)
- Age 55-85
- Positive amyloid PET or CSF biomarkers
Given your research focus on early intervention at the precise stage when these cognitive fluctuations become clinically significant, I thought some of your patients might be ideal candidates. Would you be open to discussing how this trial aligns with your current research interests?
Hi Claire,
Thank you for reaching out. I do have a 72-year-old patient with early-stage Alzheimer's disease (MMSE score of 22) who might be eligible. Their amyloid PET scan showed significant plaque buildup, and they're currently on Donepezil 10mg/day.
Do you know if the trial allows concurrent use of cholinesterase inhibitors? Also, they've shown some mild cerebral microbleeds on their recent MRI. Would this exclude them from the trial?
Hey Sara,
Thank you for your quick response and for considering the trial for your patient.
Yes, the protocol does allow concurrent use of cholinesterase inhibitors like Donepezil, provided the dosage has been stable for at least 3 months prior to screening. This is specifically mentioned in the inclusion criteria.
Regarding the cerebral microbleeds (CMBs), it depends on their number and location. The exclusion criteria specify:
- More than 4 microbleeds (≤10 mm) would be exclusionary
- Any microbleed >10 mm would exclude participation
- Location in the brainstem would also be exclusionary
Would you be able to provide more details about the number and location of the microbleeds from the MRI report?
I'd be happy to connect you with Dr. Alexandra Chen, the principal investigator at the Georgetown site, for further discussion about your patient.
Claire,
Thanks for the quick and detailed response. The patient has been on a stable dose of Donepezil for 8 months, so that shouldn't be an issue.
I've reviewed the MRI report again, and there are only 2 microbleeds, both located in the right parietal lobe and both under 5mm in diameter. Based on what you've shared, it seems they would still be eligible.
I'd appreciate a connection with Dr. Chen. The patient is quite functional but showing increasing word-finding difficulties and spatial disorientation. Their family is very motivated to explore all treatment options.
Eligibility Assessment
Unlike standard recruitment methods, we can immediately evaluate patient eligibility details, addressing clinical questions and reducing screening failures.
50% Faster Recruitment
Our targeted approach consistently cuts recruitment timelines in half, saving millions in development costs and accelerating time-to-market.
Our Global Recruitment Network
AI-powered outreach across borders, languages, and healthcare systems—maintaining perfect protocol accuracy worldwide.
Physicians & Principal Investigators across the globe connected to our AI system
Languages processed in real-time
Countries with active recruitment
Unmatched scalability
Our AI processes thousands of clinical conversations every minute
Multilingual Precision
Our AI maintains clinical accuracy across all languages while adapting to cultural communication styles and regional healthcare protocols.
Regulatory Adaptive
Automatically conforms to local regulatory requirements across all regions while maintaining consistent trial protocol interpretation.
Real-time Insights
Global recruitment dashboard showing live engagement metrics across all regions with predictive recruitment timelines.
Onboarding in a day
Integrate Boff AI into your workflow in days—not weeks. Our interface is your email—no complicated setups or learning curves.
Share your trial details
We build a targeted physician list
Launch AI-driven outreach
Hand over interested leads
Share your trial details
Simply share your protocol document and contact information via email. That's it.
We build a targeted physician list
Our AI identifies the perfect physicians most likely to have eligible patients.
Launch AI-driven outreach
Our system begins personalized communication—all through their existing email.
Hand over interested leads
We connect you directly with each interested physician through your regular email.
It's really that simple
Effortless integration through your existing email. No new logins, no software to learn, no installation required.
Setup time
Potential time savings
Industry Standard vs. Boff AI
Why settle for slow? Here's how traditional recruitment compares with Boff AI.
Traditional Recruitment
Time to Recruit:
6-12 months (Phase III)
Cost per Patient:
$10,000+
Process:
Relies on manual outreach, heavy labor costs, and unpredictable delays
Boff AI Recruitment
Time to Recruit:
3-6 months (Phase III)
Cost Savings:
Reduced labor and operational expenses
Process:
AI-driven, scalable outreach with human oversight—faster and more efficient
ROI Calculator: Estimate Your Savings
Discover how much Boff AI can save on your trial's recruitment costs. Choose a trial phase or input your own budget for a custom estimate.
1Select Your Trial Phase:
IPhase I
IIPhase II
âś“Phase III
2Or Calculate Your Own Savings:
How It Works
Boff AI cuts recruitment time by up to 50%, reducing time-dependent costs like staffing and site fees. We assume 50% of your recruitment budget is time-dependent, so halving that portion typically saves 25% of the total recruitment cost.
Note: Actual savings may vary depending on your trial's specifics.
What Industry Leaders Say
"Boff AI transformed our recruitment strategy. We reached our patient enrollment targets 42% faster than our previous Phase II trial."
Clinical Trial Director
Pharma"The personalized outreach to physicians yielded engagement rates we've never seen before. Our study filled in record time with qualified patients."
VP of Clinical Operations
Biotech"As a principal investigator, I've seen many recruitment solutions. Boff AI stands out by connecting us with genuinely interested physicians who have eligible patients."
Principal Investigator
CRO